1-氟-1-去[2-[(2-羟基乙基)氨基]乙基氨基]米托蒽醌 | 1195810-93-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 中文名称: 1-氟-1-去[2-[(2-羟基乙基)氨基]乙基氨基]米托蒽醌
• 英文名称: 1-fluoro-5,8-dihydroxy-4-((2-((2-hydroxyethyl)amino)ethyl)amino)anthracene-9,10-dione
• 英文别名: 1-Fluoro-1-des[2-[(2-Hydroxyethyl)amino]ethylamino] Mitoxantrone；1-fluoro-5,8-dihydroxy-4-[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
• CAS: 1195810-93-5
• 化学式: C₁₈H₁₇FN₂O₅
• 分子量: 360.342
• InChiKey: GQUHUXAZQAECFA-UHFFFAOYSA-N

物化性质

• 溶解度：
  二甲基亚砜、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  119
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1-氟-1-去[2-[(2-羟基乙基)氨基]乙基氨基]米托蒽醌 在 ammonium hydroxide 作用下， 以 吡啶 为溶剂， 反应 2.0h， 以50%的产率得到去[2-[(2-羟基乙基)氨基]乙基]米托蒽醌
  参考文献：
  名称：

  Mitoxantrone Analogues as Ligands for a Stem−Loop Structure of Tau Pre-mRNA

  摘要：

  A series of mitoxantrone (MTX) analogues have been designed, synthesized, and evaluated for binding to and stabilizing a stern-loop structure that serves as a splicing regulatory element in the pre-mRNA of tau, which is involved in Alzheimer's and other neurodegenerative diseases. Several compounds showed significantly improved binding activity relative to the original screening hit mitoxantrone. These findings establish essential structure-activity relationships to further optimize the activity of this promising class of compounds.

  DOI：

  10.1021/jm9013407
• 作为产物：
  描述：

  1,4-二氟-5,8-二羟基蒽醌 、 羟乙基乙二胺 以 吡啶 为溶剂， 反应 1.0h， 以50%的产率得到1-氟-1-去[2-[(2-羟基乙基)氨基]乙基氨基]米托蒽醌
  参考文献：
  名称：

  Mitoxantrone Analogues as Ligands for a Stem−Loop Structure of Tau Pre-mRNA

  摘要：

  A series of mitoxantrone (MTX) analogues have been designed, synthesized, and evaluated for binding to and stabilizing a stern-loop structure that serves as a splicing regulatory element in the pre-mRNA of tau, which is involved in Alzheimer's and other neurodegenerative diseases. Several compounds showed significantly improved binding activity relative to the original screening hit mitoxantrone. These findings establish essential structure-activity relationships to further optimize the activity of this promising class of compounds.

  DOI：

  10.1021/jm9013407

文献信息

• Approved Anti-cancer Drugs Target Oncogenic Non-coding RNAs
  作者：Sai Pradeep Velagapudi、Matthew G. Costales、Balayeshwanth R. Vummidi、Yoshio Nakai、Alicia J. Angelbello、Tuan Tran、Hafeez S. Haniff、Yasumasa Matsumoto、Zi Fu Wang、Arnab K. Chatterjee、Jessica L. Childs-Disney、Matthew D. Disney

  DOI：10.1016/j.chembiol.2018.05.015

  日期：2018.9

  Potential RNA drug targets for small molecules are found throughout the human transcriptome, yet small molecules known to elicit a pharmacological response by directly targeting RNA are limited to antibacterials. Herein, we describe AbsorbArray, a small molecule microarray-based approach that allows for unmodified compounds, including FDA-approved drugs, to be probed for binding to RNA motif libraries

  在整个人类转录组中都发现了小分子的潜在RNA药物靶标，但是已知通过直接靶向RNA引起药理反应的小分子仅限于抗菌剂。在本文中，我们描述了AbsorbArray，这是一种基于小分子微阵列的方法，允许以未经修饰的化合物（包括FDA批准的药物）以大规模平行形式与RNA基序文库结合进行探测。几种药物结合RNA，包括激酶和拓扑异构酶抑制剂。后者与致癌microRNA（miR）-21的Dicer位点中发现的基序紧密结合，并在体外和细胞中均抑制了其加工。最有效的化合物可抑制下游蛋白质靶标并抑制miR-21介导的侵袭性表型。该化合物的活性在pre-miR-21过表达时被消除。